IBIO
iBio, Inc.
Price Chart
Latest Quote
$1.62
-0.03 (-1.82%)
Current Price
| Previous Close | $1.65 |
| Open | $1.68 |
| Day High | $1.69 |
| Day Low | $1.62 |
| Volume | 397,848 |
Stock Information
| Shares Outstanding | 49.68M |
| Total Debt | $2.33M |
| Cash Equivalents | $74.80M |
| Revenue | $300K |
| Net Income | $-27.61M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $80.48M |
| EPS (TTM) | $-0.56 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $8.01M |
| Sales | $300K |
| Income | $-27.61M |
| Book/sh | $2.25 |
| Cash/sh | $1.51 |
| Employees | 20 |
Financial Ratios
| Quick Ratio | 11.50 |
| Current Ratio | 11.88 |
| Debt/Eq | 3.00 |
Returns & Margins
| ROA | -34.50% |
| ROE | -62.09% |
| Gross Margin | 100.00% |
| Operating Margin | -9653.00% |
Ownership
| Insider Ownership | 1.71% |
| Institutional Ownership | 48.65% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.23 |
| P/S | 268.26 |
| P/B | 0.72 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $5.53 |
Technical Indicators
| SMA20 | $1.75 |
| SMA50 | $1.75 |
| SMA200 | $1.74 |
| RSI | 36.59 |
| ATR | 0.1343 |
| Shares Float | 41.21M |
| Short Float | 7.61% |
| Short Ratio | 3.82 |
| Volatility | 1.26 |
| Rel Volume | 0.49 |
Performance History
| Week | +4.52% |
| Month | -11.96% |
| Quarter | -22.12% |
| 6 Months | -18.18% |
| YTD | -19.80% |
| Year | +128.17% |
| 3 Years | -88.43% |
| 5 Years | -99.79% |
| 10 Years | -99.95% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $1.62 | 398,900 |
| 2026-06-23 | $1.65 | 931,000 |
| 2026-06-22 | $1.74 | 904,700 |
| 2026-06-18 | $1.69 | 912,100 |
| 2026-06-17 | $1.60 | 1,671,100 |
| 2026-06-16 | $1.55 | 1,049,300 |
| 2026-06-15 | $1.65 | 751,800 |
| 2026-06-12 | $1.69 | 453,600 |
| 2026-06-11 | $1.67 | 353,400 |
| 2026-06-10 | $1.70 | 507,200 |
| 2026-06-09 | $1.70 | 410,000 |
| 2026-06-08 | $1.73 | 641,600 |
| 2026-06-05 | $1.82 | 2,285,500 |
| 2026-06-04 | $1.93 | 854,800 |
| 2026-06-03 | $1.84 | 725,400 |
| 2026-06-02 | $1.76 | 1,136,800 |
| 2026-06-01 | $1.89 | 524,300 |
| 2026-05-29 | $1.90 | 317,600 |
| 2026-05-28 | $1.93 | 745,300 |
| 2026-05-27 | $1.88 | 593,000 |
| 2026-05-26 | $1.82 | 1,101,600 |
About iBio, Inc.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2Âexpressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
đ° Latest News
Could iBio (IBIO) Be an Underrated Obesity Stock?
Insider Monkey âĸ 2026-06-12T00:37:05Z
We're Not Very Worried About iBio's (NASDAQ:IBIO) Cash Burn Rate
Simply Wall St. âĸ 2026-05-15T10:28:22Z
iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600
Insider Monkey âĸ 2026-04-24T19:14:46Z
iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close âTrust Gapâ
MarketBeat âĸ 2026-04-08T22:13:21ZiBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3
MarketBeat âĸ 2026-03-20T08:28:48Z
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
Zacks âĸ 2026-02-03T15:00:11Z
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Zacks âĸ 2026-02-02T15:00:05Z
iBio Insiders Placed Bullish Bets Worth US$655.0k
Simply Wall St. âĸ 2025-12-20T12:07:24Z
BC-Most Active Stocks
Associated Press Finance âĸ 2025-12-10T15:30:18ZiBio, Inc. (IBIO) Reports Q1 Loss
Zacks âĸ 2025-11-12T22:15:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $400,000 | $225,000 | $0 | $1,884,000 |
| Operating Revenue | $400,000 | $225,000 | $0 | $1,884,000 |
| Reconciled Cost Of Revenue | - | - | - | $216,000 |
| Cost Of Revenue | - | - | - | $216,000 |
| Expenses | ||||
| Interest Expense | $212,000 | $172,000 | $83,000 | $0 |
| Total Expenses | $19,002,000 | $16,859,000 | $29,343,000 | $31,581,000 |
| Net Non Operating Interest Income Expense | $225,000 | $191,000 | $130,000 | $177,000 |
| Interest Expense Non Operating | $212,000 | $172,000 | $83,000 | $0 |
| Operating Expense | $19,002,000 | $16,859,000 | $29,343,000 | $31,581,000 |
| General And Administrative Expense | $10,690,000 | $11,674,000 | $19,016,000 | $21,754,000 |
| Other Income Expense | - | $1,000,000 | $-98,000 | $7,000 |
| Other Non Operating Income Expenses | - | - | - | $7,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-18,377,000 | $-15,443,000 | $-29,311,000 | $-29,512,000 |
| Net Interest Income | $225,000 | $191,000 | $130,000 | $177,000 |
| Interest Income | $437,000 | $363,000 | $213,000 | $177,000 |
| Normalized Income | $-18,377,000 | $-16,443,000 | $-29,213,000 | $-29,512,000 |
| Net Income From Continuing And Discontinued Operation | $-18,377,000 | $-24,907,000 | $-65,010,000 | $-50,303,000 |
| Total Operating Income As Reported | $-18,602,000 | $-16,634,000 | $-29,343,000 | $-29,697,000 |
| Net Income Common Stockholders | $-18,377,000 | $-24,907,000 | $-65,010,000 | $-50,391,000 |
| Net Income | $-18,377,000 | $-24,907,000 | $-65,010,000 | $-50,391,000 |
| Net Income Including Noncontrolling Interests | $-18,377,000 | $-24,907,000 | $-65,010,000 | $-50,392,000 |
| Net Income Discontinuous Operations | $0 | $-9,464,000 | $-35,699,000 | $-20,791,000 |
| Net Income Continuous Operations | $-18,377,000 | $-15,443,000 | $-29,311,000 | $-29,513,000 |
| Pretax Income | $-18,377,000 | $-15,443,000 | $-29,311,000 | $-29,513,000 |
| Special Income Charges | $0 | $1,000,000 | $0 | $607,000 |
| Interest Income Non Operating | $437,000 | $363,000 | $213,000 | $177,000 |
| Operating Income | $-18,602,000 | $-16,634,000 | $-29,343,000 | $-29,697,000 |
| Net Income From Tax Loss Carryforward | - | - | $0 | $-88,000 |
| Gross Profit | - | - | - | $2,167,000 |
| Per Share | ||||
| Diluted EPS | $-1.75 | $-6.50 | $-106.19 | $-115.60 |
| Basic EPS | $-1.75 | $-6.50 | $-106.19 | $-115.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-17,039,000 | $-15,021,000 | $-27,750,000 | $-25,722,000 |
| Total Unusual Items | $0 | $1,000,000 | $-98,000 | $607,000 |
| Total Unusual Items Excluding Goodwill | $0 | $1,000,000 | $-98,000 | $607,000 |
| Reconciled Depreciation | $1,126,000 | $1,250,000 | $1,380,000 | $3,791,000 |
| EBITDA (Bullshit earnings) | $-17,039,000 | $-14,021,000 | $-27,848,000 | $-25,722,000 |
| EBIT | $-18,165,000 | $-15,271,000 | $-29,228,000 | $-29,513,000 |
| Diluted Average Shares | $10,499,000 | $3,831,000 | $612,000 | $436,050 |
| Basic Average Shares | $10,499,000 | $3,831,000 | $612,000 | $436,050 |
| Diluted NI Availto Com Stockholders | $-18,377,000 | $-24,907,000 | $-65,010,000 | $-50,391,000 |
| Gain On Sale Of Ppe | $0 | $1,000,000 | $0 | - |
| Research And Development | $8,312,000 | $5,185,000 | $10,327,000 | $9,827,000 |
| Selling General And Administration | $10,690,000 | $11,674,000 | $19,016,000 | $21,754,000 |
| Other Gand A | $10,690,000 | $11,674,000 | $19,016,000 | $21,754,000 |
| Minority Interests | - | - | $0 | $1,000 |
| Gain On Sale Of Security | - | - | $-98,000 | - |
| Preferred Stock Dividends | - | - | - | $88,000 |
| Other Special Charges | - | - | - | $-607,000 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $8,032,000 | $15,956,000 | $9,993,000 | $58,634,000 |
| Total Assets | $23,185,000 | $28,734,000 | $41,207,000 | $99,406,000 |
| Total Non Current Assets | $13,464,000 | $13,062,000 | $14,948,000 | $54,336,000 |
| Other Non Current Assets | $210,000 | $215,000 | $253,000 | $43,310,000 |
| Non Current Prepaid Assets | $26,000 | $26,000 | $50,000 | $103,000 |
| Non Current Note Receivables | $1,098,000 | $1,081,000 | $1,706,000 | $1,631,000 |
| Goodwill And Other Intangible Assets | $6,848,000 | $5,368,000 | $5,388,000 | $4,851,000 |
| Other Intangible Assets | $6,848,000 | $5,368,000 | $5,388,000 | $4,851,000 |
| Current Assets | $9,721,000 | $15,672,000 | $26,259,000 | $45,070,000 |
| Other Current Assets | $1,034,000 | $749,000 | $664,000 | $1,549,000 |
| Receivables | $105,000 | $713,000 | $204,000 | $6,100,000 |
| Other Receivables | $105,000 | - | $204,000 | $5,100,000 |
| Notes Receivable | $0 | $713,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $8,582,000 | $14,210,000 | $4,301,000 | $33,521,000 |
| Cash And Cash Equivalents | $8,582,000 | $14,210,000 | $4,301,000 | $22,676,000 |
| Assets Held For Sale Current | - | $0 | $18,065,000 | $3,900,000 |
| Restricted Cash | - | $0 | $3,025,000 | $0 |
| Accounts Receivable | - | - | $0 | $1,000,000 |
| Prepaid Assets | - | - | - | $1,549,000 |
| Inventory | - | - | - | $3,900,000 |
| Non Current Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $3,508,000 | $4,460,000 | $17,074,000 | $25,766,000 |
| Long Term Debt And Capital Lease Obligation | $2,199,000 | $3,507,000 | $3,476,000 | $3,514,000 |
| Current Debt And Capital Lease Obligation | $1,309,000 | $953,000 | $13,598,000 | $22,252,000 |
| Current Debt | $766,000 | $218,000 | $12,937,000 | $22,161,000 |
| Other Current Borrowings | $766,000 | $218,000 | - | - |
| Long Term Debt | - | $766,000 | - | - |
| Net Debt | - | - | $8,636,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,305,000 | $7,410,000 | $25,826,000 | $35,921,000 |
| Total Non Current Liabilities Net Minority Interest | $2,199,000 | $3,570,000 | $3,717,000 | $5,485,000 |
| Tradeand Other Payables Non Current | $0 | $63,000 | $241,000 | $0 |
| Current Liabilities | $6,106,000 | $3,840,000 | $22,109,000 | $30,436,000 |
| Current Deferred Liabilities | $1,200,000 | $200,000 | $0 | $100,000 |
| Payables And Accrued Expenses | $2,721,000 | $1,119,000 | $2,691,000 | $8,028,000 |
| Payables | $2,252,000 | $659,000 | $2,277,000 | $4,548,000 |
| Other Payable | $64,000 | $301,000 | $160,000 | - |
| Accounts Payable | $2,188,000 | $358,000 | $1,849,000 | $4,264,000 |
| Current Notes Payable | - | $0 | $12,937,000 | $22,161,000 |
| Interest Payable | - | $0 | $183,000 | $59,000 |
| Total Tax Payable | - | $0 | $268,000 | $284,000 |
| Liabilities Heldfor Sale Non Current | - | - | $0 | $1,971,000 |
| Other Current Liabilities | - | - | $1,941,000 | $56,000 |
| Equity | ||||
| Common Stock Equity | $14,880,000 | $21,324,000 | $15,381,000 | $63,485,000 |
| Total Equity Gross Minority Interest | $14,880,000 | $21,324,000 | $15,381,000 | $63,485,000 |
| Stockholders Equity | $14,880,000 | $21,324,000 | $15,381,000 | $63,485,000 |
| Retained Earnings | $-332,224,000 | $-313,847,000 | $-288,940,000 | $-223,930,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | $0 | $-213,000 |
| Other Equity Adjustments | - | - | - | $-213,000 |
| Other | ||||
| Ordinary Shares Number | $19,349,201 | $8,623,676 | $1,015,503 | $436,357 |
| Share Issued | $19,349,201 | $8,623,676 | $1,015,503 | $436,357 |
| Tangible Book Value | $8,032,000 | $15,956,000 | $9,993,000 | $58,634,000 |
| Invested Capital | $15,646,000 | $22,308,000 | $28,318,000 | $85,646,000 |
| Working Capital | $3,615,000 | $11,832,000 | $4,150,000 | $14,634,000 |
| Capital Lease Obligations | $2,742,000 | $3,476,000 | $4,137,000 | $3,605,000 |
| Total Capitalization | $14,880,000 | $22,090,000 | $15,381,000 | $63,485,000 |
| Additional Paid In Capital | $347,085,000 | $335,162,000 | $304,320,000 | $287,619,000 |
| Capital Stock | $19,000 | $9,000 | $1,000 | $9,000 |
| Common Stock | $19,000 | $9,000 | $1,000 | $9,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $2,199,000 | $2,741,000 | $3,476,000 | $3,514,000 |
| Current Deferred Revenue | $1,200,000 | $200,000 | $0 | $100,000 |
| Current Capital Lease Obligation | $543,000 | $735,000 | $661,000 | $91,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $876,000 | $1,568,000 | $3,879,000 | - |
| Current Accrued Expenses | $469,000 | $460,000 | $414,000 | $3,480,000 |
| Net PPE | $5,282,000 | $6,372,000 | $7,551,000 | $4,441,000 |
| Accumulated Depreciation | $-2,241,000 | $-1,486,000 | $-604,000 | $0 |
| Gross PPE | $7,523,000 | $7,858,000 | $8,155,000 | $4,441,000 |
| Other Properties | $2,865,000 | $3,215,000 | $3,536,000 | $3,068,000 |
| Machinery Furniture Equipment | $3,963,000 | $3,948,000 | $3,924,000 | $0 |
| Buildings And Improvements | $695,000 | $695,000 | $695,000 | $0 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | $0 | - | - |
| Non Current Accrued Expenses | - | - | $527,000 | $0 |
| Construction In Progress | - | - | $0 | $1,373,000 |
| Other Short Term Investments | - | - | $0 | $10,845,000 |
| Minority Interest | - | - | - | $0 |
| Work In Process | - | - | - | $4,000 |
| Raw Materials | - | - | - | $3,896,000 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-15,320,000 | $-18,764,000 | $-36,174,000 | $-49,110,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-15,304,000 | $-18,554,000 | $-30,436,000 | $-37,480,000 |
| Cash Flow From Continuing Operating Activities | $-15,304,000 | $-18,554,000 | $-30,436,000 | $-37,480,000 |
| Operating Gains Losses | - | $3,101,000 | $-680,000 | $-607,000 |
| Investing Activities | ||||
| Capital Expenditure | $-16,000 | $-210,000 | $-5,738,000 | $-11,630,000 |
| Investing Cash Flow | $742,000 | $906,000 | $7,009,000 | $-5,127,000 |
| Cash Flow From Continuing Investing Activities | $742,000 | $906,000 | $7,009,000 | $-5,127,000 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-7,000 | $-39,000 | $0 |
| Issuance Of Capital Stock | $3,541,000 | $25,523,000 | $11,487,000 | $0 |
| Financing Cash Flow | $8,929,000 | $24,494,000 | $2,301,000 | $-6,125,000 |
| Cash Flow From Continuing Financing Activities | $8,929,000 | $24,494,000 | $2,301,000 | $-6,125,000 |
| Net Other Financing Charges | $-294,000 | $116,000 | $-22,000 | $-372,000 |
| Net Common Stock Issuance | $3,541,000 | $25,516,000 | $11,448,000 | $0 |
| Common Stock Issuance | $3,541,000 | $25,523,000 | $11,487,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-695,000 | $-2,033,000 | $-9,625,000 | $-5,830,000 |
| Issuance Of Debt | $0 | $895,000 | $500,000 | $0 |
| Interest Paid Supplemental Data | $212,000 | $749,000 | $687,000 | $1,045,000 |
| End Cash Position | $8,792,000 | $14,425,000 | $7,579,000 | $28,672,000 |
| Beginning Cash Position | $14,425,000 | $7,579,000 | $28,672,000 | $77,404,000 |
| Changes In Cash | $-5,633,000 | $6,846,000 | $-21,126,000 | $-48,732,000 |
| Proceeds From Stock Option Exercised | $6,377,000 | $0 | $0 | $77,000 |
| Common Stock Payments | $0 | $-7,000 | $-39,000 | $0 |
| Net Issuance Payments Of Debt | $-695,000 | $-1,138,000 | $-9,125,000 | $-5,830,000 |
| Net Short Term Debt Issuance | $0 | $-1,513,000 | $-9,318,000 | $0 |
| Short Term Debt Payments | $0 | $-1,513,000 | $-9,318,000 | $0 |
| Net Long Term Debt Issuance | $-695,000 | $375,000 | $193,000 | $-5,830,000 |
| Long Term Debt Payments | $-695,000 | $-520,000 | $-307,000 | $-5,830,000 |
| Long Term Debt Issuance | $0 | $895,000 | $500,000 | $0 |
| Interest Received Cfi | $758,000 | $0 | - | - |
| Net Intangibles Purchase And Sale | $0 | $1,000,000 | $0 | $-4,300,000 |
| Sale Of Intangibles | $0 | $1,000,000 | $0 | - |
| Net PPE Purchase And Sale | $-16,000 | $-94,000 | $-3,138,000 | $-7,330,000 |
| Sale Of PPE | $0 | $116,000 | $2,600,000 | $0 |
| Purchase Of PPE | $-16,000 | $-210,000 | $-5,738,000 | $-7,330,000 |
| Change In Working Capital | $479,000 | $-3,168,000 | $5,869,000 | $3,243,000 |
| Change In Other Working Capital | $250,000 | $200,000 | $-100,000 | $7,000 |
| Change In Other Current Liabilities | $-436,000 | $-389,000 | $-101,000 | $-15,000 |
| Change In Payables And Accrued Expense | $1,073,000 | $-3,217,000 | $47,000 | $2,682,000 |
| Change In Accrued Expense | $-758,000 | $-1,726,000 | $672,000 | $1,443,000 |
| Change In Payable | $1,831,000 | $-1,491,000 | $-625,000 | $1,239,000 |
| Change In Account Payable | $1,831,000 | $-1,491,000 | $-625,000 | $1,239,000 |
| Change In Prepaid Assets | $-408,000 | $238,000 | $938,000 | $228,000 |
| Other Non Cash Items | $-62,000 | $32,000 | $167,000 | $-52,000 |
| Stock Based Compensation | $1,530,000 | $2,038,000 | $4,391,000 | $4,377,000 |
| Asset Impairment Charge | $0 | $3,100,000 | $18,465,000 | $1,760,000 |
| Depreciation Amortization Depletion | $1,126,000 | $1,250,000 | $1,380,000 | $3,791,000 |
| Depreciation And Amortization | $1,126,000 | $1,250,000 | $1,380,000 | $3,791,000 |
| Amortization Cash Flow | $20,000 | $20,000 | $126,000 | $401,000 |
| Amortization Of Intangibles | $20,000 | $20,000 | $126,000 | $401,000 |
| Depreciation | $1,106,000 | $1,230,000 | $1,254,000 | $3,390,000 |
| Gain Loss On Sale Of PPE | $0 | $3,909,000 | $-773,000 | $0 |
| Net Income From Continuing Operations | $-18,377,000 | $-24,907,000 | $-65,010,000 | $-50,304,000 |
| Effect Of Exchange Rate Changes | - | $0 | $33,000 | $0 |
| Net Investment Purchase And Sale | - | $0 | $10,839,000 | $6,503,000 |
| Sale Of Investment | - | $0 | $10,839,000 | $13,618,000 |
| Net Business Purchase And Sale | - | $0 | $-692,000 | $0 |
| Purchase Of Business | - | $0 | $-692,000 | $0 |
| Change In Inventory | - | $0 | $-1,015,000 | $-3,873,000 |
| Change In Receivables | - | $0 | $6,100,000 | $4,214,000 |
| Changes In Account Receivables | - | $0 | $1,000,000 | $-886,000 |
| Provisionand Write Offof Assets | - | $0 | $4,915,000 | $0 |
| Amortization Of Securities | - | $0 | $67,000 | $312,000 |
| Purchase Of Investment | - | - | $0 | $-7,115,000 |
| Purchase Of Intangibles | - | - | $0 | $-4,300,000 |
| Gain Loss On Investment Securities | - | - | $98,000 | - |
Fetched: 2026-06-24